mRNA-Transfection of adult progenitor cells for specific tissue regeneration

What: ***Asset acquisition, assignment of patent***

For whom: ***Strong development & marketing partner in this field***

Technology

- Progenitor cells, other than human embryonal stem cells, that are transfected with mRNA, encoding a protein that promotes (a) homing of progenitor cells into a target tissue and/or (b) differentiation of progenitor cells into target cells or target tissue..

- Benefits for assignee
  - Full control over patent in Ep, US and JP
  - Technology and market securing
  - New therapeutic chance for tissue engineering or regeneration and generating transplantable tissue.

Innovation

- Use of mRNA to transfect progenitor cells to promote homing to a specific type of target tissue or to promote the differentiation in cells oaf a specific type of target tissue.

Application

- To be used for therapeutic purposes to regenerate tisue

Developmental Status

- Lab tests, and prove of principle

Responsible Scientist

Prof. Dr. Jan Torzewski
Ulm University
Department of Internal Medicine II

Branch

Health care, Biotechnology, Research

Patent Status

EP. US De patent pending

Reference Number

PVAUlm369

Status: Aug-14

CTF – The R & D Company of the Freiburg University and the Freiburg University Medical Center

Contact

Dr. Claudia Skamel
Campus Technologies Freiburg GmbH
Stefan-Meier-Str. 8 | D-79104 Freiburg
Email: Claudia.Skamel@campus-technologies.de
Tel: +49 (0)761 203-4987
Fax:+49 (0)761 203-5021